Tactics of management of patients with refractory GERD


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

At present, it is assumed that the proportion of patients with gastroesophageal reflux disease (GERD), who does not fully respond to proton pump inhibitors (PPIs), is about 30% of all patients. The main goal of the management of these patients is a careful examination with definition of disease phenotype. In patients with evidence of pathological acid reflux, choice should be made in favor of the activation of acid-suppressive therapy (PPI, alginates). In other cases, PPIs are combined with drugs that affect the tone of the lower esophageal sphincter (baclofen), motility (prokinetics), hypersensitivity of the esophagus (antidepressants). Surgical treatment requires careful examination and represents a possible approach to the management of patients with refractory GERD.

全文:

受限制的访问

作者简介

V. Tsukanov

FSBEI Federal Research Center “Krasnoyarsk Scientific Center" of Siberian Branch of the Russian Academy of Sciences; Scientific Research Institute of Medical Problems of the North

Email: gastro@impn.ru
MD, Prof, Head of the Clinical Department of Pathology of the Digestive System in Children and Adults

E. Kasparov

FSBEI Federal Research Center “Krasnoyarsk Scientific Center" of Siberian Branch of the Russian Academy of Sciences; Scientific Research Institute of Medical Problems of the North

A. Vasyutin

FSBEI Federal Research Center “Krasnoyarsk Scientific Center" of Siberian Branch of the Russian Academy of Sciences; Scientific Research Institute of Medical Problems of the North

Yu. Tonkikh

FSBEI Federal Research Center “Krasnoyarsk Scientific Center" of Siberian Branch of the Russian Academy of Sciences; Scientific Research Institute of Medical Problems of the North

参考

  1. Sifrim D., Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9): 1340-54.
  2. Scarpellini E., Ang D., Pauwels A., De Santis A., Vanuytsel T., Tack J. Management of refractory typical GERD symptoms. Nat. Rev. Gastroenterol. Hepatol. 2016;13(5):281-94.
  3. Hershcovici T., Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis. Esophagus. 2013;26(1):27-36.
  4. Ates F., Francis D.O., Vaezi M.F. Refractory gastroesophageal reflux disease: advances and treatment. Expert Rev. Gastroenterol. Hepatol. 2014;8(6):657-67.
  5. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013;108(3):308-28.
  6. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006;101(8):1900-20.
  7. Fass R., Gasiorowska A. Refractory GERD: what is it?Curr. Gastroenterol. Rep. 2008;10(3):252-7.
  8. Boeckxstaens G., El-Serag H.B., Smout A.J., Kahrilas P.J. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-93.
  9. Цуканов В.В., Онучина Е.В., Васютин А.В., Буторин Н.Н., Амельчугова О.С. Клинические аспекты гастроэзофагеальной рефлюксной болезни у лиц пожилого возраста: результаты 5-летнего проспективного исследования. Тер. арх. 2014;2:23-6.
  10. Vaezi M.F., Richter J.E., Stasney C.R., Spiegel J.R., lannuzzi R.A., Crawley J.A, Hwang C., Sostek M.B., Shaker R. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116(2):254-60.
  11. Zerbib F., Belhocine K., Simon M., Capdepont M., Mion F., Bruley des Varannes S., Galmiche J.P Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61(4):501-6.
  12. Hirano I., Richter J.E. ACG practice guidelines: esophageal reflux testing. Am. J. Gastroenterol. 2007;102(3):668-85.
  13. De Groot N.L., Burgerhart J.S., Van De Meeberg P.C., de Vries D.R., Smout A.J., Siersema P.D. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2009;30(11-12): 1091-102.
  14. Eherer AJ., Netolitzky F., Högenauer C., Puschnig G., Hinterleitner T.A., Scheidl S., Kraxner W., Krejs G.J., Hoffmann K.M. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am. J. Gastroenterol. 2012;107(3):372-78.
  15. Manabe N., Haruma K., Ito M., Takahashi N., Takasugi H., Wada Y., Nakata H., Katoh T., Miyamoto M., Tanaka S. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis. Esophagus. 2012;25(5):373-80.
  16. Tack J., Zaninotto G. Therapeutic options in oesophageal dysphagia. Nat. Rev. Gastroenterol. Hepatol. 2015;12(6):332-41.
  17. Koek G.H., Sifrim D., Lerut T., Janssens J., Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastrooesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397-402.
  18. Цуканов В.В., Онучина Е.В., Каспаров Э.В., Васютин А.В., Тонких Ю.Л. Опыт длительной терапии пациентов с пищеводом Барретта. Фарматека. 2015;2:62-5.
  19. Forcelini C.M., Tomiozzo J.C., Farré R., Van Oudenhove L., Callegari-Jacques S.M., Ribeiro M., Madalosso B.H., Fornari F. Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease. Neurogastroenterol. Motil. 2014;26(2):187-95.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##